Cerebrospinal fluid in HIV-1 systemic viral controllers: Absence of HIV-1 RNA and intrathecal inflammation

AIDS

Volumn 24, Issue 7, 2010, Pages 1001-1005

  Probasco, John C ^a,b   Deeks, Steven G ^a   Lee, Evelyn ^a   Hoh, Rebecca ^a   Hunt, Peter W ^a   Liegler, Teri ^a   Price, Richard W ^a   Spudich, Serena S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Central nervous system; Cerebrospinal fluid; HIV controllers; HIV RNA; Intrathecal inflammation

Indexed keywords

ALBUMIN; ANTIRETROVIRUS AGENT; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MONOCYTE CHEMOTACTIC PROTEIN 1; NEOPTERIN; VIRUS RNA;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFLAMMATION; INTRATHECAL INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV SERONEGATIVITY; HIV-1; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MYELITIS; RNA, VIRAL; SPINAL CORD; VIRAL LOAD;

EID: 77950920115     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328331e15b     Document Type: Article

References (32)

1. Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007; 27:406-416.
2. Walker BD. HIV controllers: an untapped source of clues to overcoming HIV infection. Res Initiat Treat Action 2007; 12:21-22.
3. Mikhail M, Wang B, Saksena NK. Mechanisms involved in nonprogressive HIV disease. AIDS Rev 2003; 5:230-244.
4. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, et al. Relationship between T cell activation and CD4R T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197:126-133.
5. Ellis RJ, Hsia K, Spector SA, Nelson JA, Heaton RK, Wallace MR, et al. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol 1997; 42:679-688.
6. Gisslen M, Fuchs D, Svennerholm B, Hagberg L. Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrosp-inal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr 1999; 21:271-276.
7. Gisslen M, Hagberg L, Fuchs D, Norkrans G, Svennerholm B. Cerebrospinal fluid viral load in HIV-1-infected patients without antiretroviral treatment: a longitudinal study. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:291-295.
8. Price RW, Staprans S. Measuring the 'viral load' in cerebrosp-inal fluid in human immunodeficiency virus infection: window into brain infection? Ann Neurol 1997; 42:675-678.
9. Navia BA, Cho ES, Petito CK, Price RW. The AIDS dementia complex. II: Neuropathology. Ann Neurol 1986; 19:525-535.
10. Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis 1988; 158:1079-1083.
11. Eden A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslen M. Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis 2007; 196:1779-1783.
12. Yilmaz A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslen M. Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 47:168-173.
13. Spudich S, Lollo N, Liegler T, Deeks SG, Price RW. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis 2006; 194:1686-1696.
14. Price RW, PaxinosEE, Grant RM, DrewsB,NilssonA,HohR,etal. Cerebrospinal fluid response to structured treatment interruption after virological failure. AIDS 2001; 15:1251-1259.
15. Spudich SS, Nilsson AC, Lollo ND, Liegler T, Petropoulos C, Deeks S, et al. Cerebrospinal fluid HIV infection and pleocy-tosis: Relation to systemic infection and antiretroviral treatment. BMC Infect Dis 2005; 5:98.
16. Havlir DV, Bassett R, Levitan D, Gilbert P, Tebas P, Collier A, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 2001; 286:171-179.
17. Huber C,Batchelor JR, Fuchs D,Hausen A,Lang A, Niederwieser D, et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interfer-on-gamma. J Exp Med 1984; 160:310-316.
18. Abdulle S, Hagberg L, Svennerholm B, Fuchs D, Gisslen M. Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection. AIDS 2002; 16:2145-2149.
19. Cinque P, Vago L, Mengozzi M, Torri V, Ceresa D, Vicenzi E, et al. Elevated cerebrospinal fluid levels of monocyte chemo-tactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS 1998; 12:1327-1332.
20. Kolb SA, Sporer B, Lahrtz F, Koedel U, Pfister H, Fontana A. Identification of a T cell chemotactic factor in cerevrospinal fluid of HIV-1-infected individuals as interferon-g inducible protein 10. J Neuroimmunol 1999; 93:172-181.
21. Cinque P, Bestetti A, Marenzi R, Sala S, Gisslen M, Hagberg L, Price RW. Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection. J Neuroimmu-nol 2005; 168:154-163. (Pubitemid 41396413)
22. Berger JR, Avison M. The blood brain barrier in HIV infection. Front Biosci 2004; 9:2680-2685.
23. Andersson LM, HagbergL, Fuchs D, Svennerholm B, Gisslen M. Increased blood-brain barrier permeability in neuro-asympto-matic HIV-1-infected individuals: correlation with cerebrosp-inal fluid HIV-1 RNA and neopterin levels. J Neurovirol 2001; 7:542-547.
24. Emu B, Sinclair E, Favre D, Moretto WJ, Hsue P, Hoh R, et al. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol 2005; 79:14169-14178.
25. Saez-Cirion A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cyto-toxic T lymphocyte activation phenotype. Proc Natl Acad Sci USA 2007; 104:6776-6781.
26. Hatano H, Delwart EL, Norris PJ, Lee TH, Dunn-Williams J, Hunt PW, et al. Evidence for persistent low-level viremia in individuals who control HIV in the absence of antiretroviral therapy. J Virol 2009; 83:329-335.
27. Ferre AL, Hunt PW, Critchfield JW, Young D, Morris M, Garcia J, et al. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 2009; 113:3978-3989.
28. Hsue PY, Hunt PW, Schnell A, Kalapus SC, Hoh R, Ganz P, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009; 23: 1059-1067.
29. Price RW. The two faces of HIV infection of cerebrospinal fluid. Trends Microbiol 2000; 8:387-391.
30. Marra CM, Maxwell CL, Collier AC, Robertson KR, Imrie A. Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy. BMC Infect Dis 2007; 7:37.
31. HagbergL,DotevallL, NorkransG, LarssonM, WachterH,Fuchs D. Cerebrospinal fluid neopterin concentrations in central nervous system infection. J Infect Dis 1993; 168:1285-1288.
32. Sinclair E, Ronquillo R, Lollo N, Deeks S, Hunt P, Yiannoutsos C, et al. Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr 2008; 47:544-552.